---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-124837"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2025-12-29T23:59:59+00:00"
generated_at: "2026-05-16T12:04:09.103384+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics sells remaining Evrysdi royalty stake to Royalty Pharma for $240M upfront

## Summary
- Sold remaining 9.5111%/16.6666% royalty interest in Evrysdi worldwide net sales for $240M upfront cash.
- Up to three additional $20M payments contingent on Royalty Pharma receiving >$347M (2027), $363M (2028), $379M (2029) in royalty payments.
- After closing, Royalty Pharma owns 100% of the Evrysdi royalty; PTC retains no interest.
- Transaction effective December 29, 2025, under Amendment No. 2 to existing royalty purchase agreement.

## SEC filing metadata
- accession: 0001104659-25-124837
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2025-12-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000110465925124837/0001104659-25-124837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000110465925124837/tmb-20251229x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-124837
- JSON: https://secwatch.observer/filing/0001104659-25-124837.json
- Plain text: https://secwatch.observer/filing/0001104659-25-124837.txt

## Key facts
- Material Agreements
  PTC THERAPEUTICS, INC. amended Amendment No. 2 to Amended and Restated Royalty Purchase Agreement with Royalty Pharma Investments 2019 ICAV valued at $240.0 million in upfront cash consideration (effective 2025-12-29).
  - Action: amendment
  - Counterparty: Royalty Pharma Investments 2019 ICAV
  - Value: $240.0 million in upfront cash consideration
  - Effective: 2025-12-29
  source text: On December 29, 2025, PTC Therapeutics, Inc. (the “Company”), Royalty Pharma Investments 2019 ICAV (“RPI”), and, for the limited purposes set forth in the Purchase Agreement (as defined below), Royalty Pharma plc, entered into an Amendment No. 2 to Amended and Restated Royalty Purchase Agreement (the “Amendment”), which amends that certain Amended and Restated Royalty Purchase Agreement, dated as of October 18, 2023, as amended by Amendment No. 1 dated June 17, 2024 (the “Purchase Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000110465925124837/0001104659-25-124837-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.